nevirapine has been researched along with Central Nervous System Diseases in 6 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "immediate allergy and increased hepatotoxicity (regardless of chronic infection with hepatitis B or C virus and methadone use) for nevirapine." | 2.71 | Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. ( Calza, L; Chiodo, F; Manfredi, R, 2004) |
| "Two hundred and thirty-five (235) AIDS patients who received ART were monitored for ADRs over a period of 6 months." | 1.36 | Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. ( Gupta, U; Kumar, S; Nagpal, M; Tayal, V, 2010) |
| "The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study." | 1.33 | Are adverse events of nevirapine and efavirenz related to plasma concentrations? ( Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pedrol, E | 1 |
| Llibre, JM | 1 |
| Tasias, M | 1 |
| Currán, A | 1 |
| Guardiola, JM | 1 |
| Deig, E | 1 |
| Guelar, A | 1 |
| Martínez-Madrid, O | 1 |
| Tikhomirova, L | 1 |
| Ramírez, R | 1 |
| Roca, B | 1 |
| Nagpal, M | 1 |
| Tayal, V | 1 |
| Kumar, S | 1 |
| Gupta, U | 1 |
| Manfredi, R | 1 |
| Calza, L | 1 |
| Chiodo, F | 1 |
| Kappelhoff, BS | 1 |
| van Leth, F | 1 |
| Robinson, PA | 1 |
| MacGregor, TR | 1 |
| Baraldi, E | 1 |
| Montella, F | 1 |
| Uip, DE | 1 |
| Thompson, MA | 1 |
| Russell, DB | 1 |
| Lange, JM | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
1 review available for nevirapine and Central Nervous System Diseases
| Article | Year |
|---|---|
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Ce | 2008 |
1 trial available for nevirapine and Central Nervous System Diseases
| Article | Year |
|---|---|
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases | 2004 |
4 other studies available for nevirapine and Central Nervous System Diseases
| Article | Year |
|---|---|
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Di | 2015 |
Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Central Nervous System Diseases; Drug Th | 2010 |
Safe substitution for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infectio | 2004 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In | 2005 |